ESMO Conference Coverage
Featured Articles
(Forbes) Oct 3, 2019 - New trial suggests that doctor's shouldn't wait to add targeted therapy drugs to standard breast cancer treatment. Results from a clinical trial show that adding ribociclib, a targeted therapy drug, to the standard treatment plan for women with advanced hormone-receptor positive/HER2- breast cancer helps...
Read Article
(Northwestern Medicine) Sept 30, 2019 - Genetic-based treatment nearly doubles time without disease progression in metastatic prostate cancer. For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially...
Read Article
Latest Articles
October 10, 2019
October 08, 2019
October 03, 2019
October 01, 2019
October 01, 2019
October 01, 2019
October 01, 2019
October 01, 2019
View More
News Commentary
Editor Image
01 Oct, 2019 | by H. Jack West, MD
The impact of the CheckMate-227 trial remains to be seen. While it was positive...
View Comment
Editor Image
01 Oct, 2019 | by H. Jack West, MD
An important result that should satisfy the holdouts who were waiting on a...
View Comment
View More
OBR Blog
By: Stephanie Hawthorne, Ph.D., Senior Director, Clinical & Scientific Assessment, Kantar Health and Tari Awipi,... Read more
September 28, 2015
By: Stephanie Hawthorne, Ph.D., Senior Director, Clinical & Scientific Assessment, Kantar Health and Len Kusdra,... Read more
September 28, 2015

OBR Tweets

Jan 27
William McGivney, PhD: The article (with totally ex-US authors) referred to was published in the British Medical Jo… https://t.co/6reunkPxAW

Jan 27
Howard S. Hochster, MD: Interesting but not overwhelming response rates, especially when compared with pretreated p… https://t.co/KFQMekfkeJ

Jan 25
Daniel Catenacci, MD, of @UChicagoMed elaborates on the outcomes of the JAVELIN 100 study presented at ASCO GI 2020… https://t.co/SLFXcH9XHW

Jan 25
Manish Shah, MD, of @WeillCornell on the role of Cyramza in the treatment of gastric and esophageal cancers #GI20 https://t.co/83LT4SouTG

Jan 25
Daniel Catenacci, MD, of @UChicagoMed discusses margetuximab in the treatment of esophageal and gastric cancer #GI20 https://t.co/bKgtxzm0tl

Jan 25
Manish Shah, MD, of @WeillCornell regarding the use of liquid biopsy to diagnose and treat GI cancers #GI20 https://t.co/PgJcHQr2IZ

Jan 25
Sam Klempner, MD, of @harvardmed explains how circulating tumor DNA can be used to help determine therapy #GI20 https://t.co/xZwsm7PSW6

Jan 25
Hani Babiker, MD, of @UAZCancer elaborates on tumor treatment fields applying to GI malignancies #GI20 https://t.co/g8OENPsK7Y

Jan 25
Hani Babiker, MD, of @UAZCancer describes the setting of FDA approval on tumor treatment fields #GI20 https://t.co/Ytzc1MwAGM

Jan 25
Ahmed Kaseb, MD, of @MDAndersonNews on combining cabozantinib with checkpoint inhibitors for treatment of HCC #GI20 https://t.co/dd7RbGGru5